Brief: Basilea Awarded Barda Contract For The Development Of Novel Oral Phase 3-Ready Antibiotic Ceftibuten-Ledaborbactam

Basilea Pharmaceutica AG, Allschwil

25/09/2025 06:17

Sept 25 (Reuters) - BASILEA PHARMACEUTICA AG ALLSCHWIL BSLN.S:

AWARDED BARDA CONTRACT FOR THE DEVELOPMENT OF NOVEL ORAL PHASE 3-READY ANTIBIOTIC CEFTIBUTEN-LEDABORBACTAM

ANNOUNCES BARDA CONTRACT NOVATION FOR ANTIBIOTIC DEVELOPMENT

REPLACES VENATORX IN BARDA CONTRACT

INITIAL FUNDING OF $6 MILLION WITH OPTIONS FOR $153 MILLION

Source text: ID:nGNE2lg736

Further company coverage: BSLN.S

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com ; +48 587785269;;))